Form 4: RenovoRx Grants 41,600 Incentive Stock Options to VP, Controller and PAO Ron Kocak

RenovoRx, Inc. has granted 41,600 incentive stock options to Ron Kocak, VP, Controller and PAO, under its 2021 Omnibus Equity Incentive Plan, with vesting commencing January 1, 2025.

Summary

• Ron Kocak, VP, Controller and PAO of RenovoRx, Inc. (RNXT), was awarded 41,600 incentive stock options.
• The options were granted under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan.
• The award was approved by the Compensation Committee of the Board of Directors on July 1, 2025.
• The issuance was contingent on the availability of shares under the Plan, which became effective after stockholder approval of an increased share reserve at the annual meeting on June 24, 2025.
• The options have an exercise price of $1.27 per share.
• Vesting occurs over four years at a rate of 1/48 per month, with no cliff, commencing on January 1, 2025.
• The options will become fully vested on January 1, 2029, and will expire on July 1, 2035.
• Exercisability is contingent upon an effective registration statement covering the underlying shares.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is a positive step for aligning management incentives with shareholder interests and retaining talent. The contingency on a registration statement is a minor point but standard for such awards.

Positives

• The award of incentive stock options aligns the interests of Ron Kocak, a key executive, with those of shareholders.
• The vesting schedule over four years encourages long-term commitment and performance from the executive.
• The approval of the increased share reserve by stockholders demonstrates support for the company's equity incentive plan.

Negatives

• The issuance of stock options can lead to potential dilution for existing shareholders if and when the options are exercised.

Risks

• The options will only become exercisable when there is an effective registration statement covering the shares underlying the option, introducing a contingency for their value realization.

Future Outlook

The options are designed to incentivize long-term performance, with vesting continuing until January 1, 2029, and exercisability contingent on a future effective registration statement.

Industry Context

Granting equity incentives like stock options to key executives is a common practice across industries, particularly in growth-oriented companies, to align management's interests with shareholder value creation and to retain talent.

Comparison to Industry Standards

• The practice of granting incentive stock options to executives is a standard compensation tool used by publicly traded companies, including those in the biotechnology and medical device sectors, to attract, retain, and motivate key personnel.
• The four-year vesting schedule with monthly vesting is a common structure for equity awards, similar to practices seen at comparable small-cap biotech firms, designed to encourage long-term employee retention and performance.
• The contingency of exercisability on an effective registration statement is a specific legal requirement for certain types of equity awards, ensuring compliance with securities laws before shares can be issued.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options, but also benefit from increased alignment of executive incentives with long-term company performance and shareholder value creation.
• Employees (specifically Ron Kocak): Receives a significant equity incentive, enhancing compensation and providing a strong motivation for long-term commitment and performance.

Next Steps

• The company needs to ensure an effective registration statement covering the shares underlying the options for them to become exercisable.
• The options will continue to vest monthly until January 1, 2029.

Key Dates

Keywords

RenovoRx, RNXT, Stock Options, Incentive Stock Options, Equity Incentive Plan, Executive Compensation, Form 4, Beneficial Ownership, Ron Kocak, Corporate Governance